Introduction
============

Psoriasis is a common chronic immune-mediated inflammatory condition characterized by complex alterations of cell signaling leading to the progression of the disease. The observed synergy between the aberrant activation of immune cells and the abnormal proliferation and differentiation of keratinocytes leads to the development of typical psoriatic symptoms---red scaly thickened plaques on the skin surface. Another feature of psoriasis is a 'cytokine storm\' that begins locally within the skin and then spreads throughout the body in form of systemic inflammation that contributes to the development of comorbidities, such as heart disease, stroke, diabetes and psoriatic arthritis.

To identify the key signaling cascades and gene expression alterations causing disease development and progression, we performed RNA-sequencing (RNA-seq) analysis of the skin transcriptome in 14 patients with psoriasis. Compared with other methods of gene expression analysis, RNA-seq provides a more precise measurement of transcription levels, a wider dynamic range of detection and more reproducible results. It was noted in Quigley^[@bib1]^ that while for the most abundant transcripts both microarray and RNA-seq produce similar results, RNA-seq is capable of identifying a large number of transcripts expressed at low levels that could not be confidently called as differentially expressed when using microarrays to analyze the same number of samples.

In this study, we present the results of RNA-seq analysis that allowed us to identify important signaling cascades enriched with differentially expressed genes (DEGs) and highlight potential transcriptional regulators contributing to the development of the disease. To identify transcriptional regulators of psoriatic pathology, we utilized two knowledge-based tools, MetaCore^[@bib2]^ and cisExpress.^[@bib3],\ [@bib4]^ Modulation of the identified signaling pathways may be a promising approach for the development of novel management strategies of psoriasis and other diseases commonly associated with this condition.^[@bib5],\ [@bib6],\ [@bib7]^

Materials and methods
=====================

Ethics statement
----------------

All steps of data collection and analysis were conducted according to the Declaration of Helsinki principles. Informed written consent was obtained from human subjects under protocols approved by the Ethics Committee of the Vavilov Institute of General Genetics, Russian Academy of Sciences.

Patients and samples
--------------------

The patients in this study were unrelated Caucasian individuals with the plaque form of psoriasis from the Bryansk regional STD and Dermatology Center. The metadata for the patients are presented in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. Two 4-mm punch biopsy specimens were taken from the skin of the patients, one from the lesional area of the skin (LS sample) and another from the non-lesional area of skin 3--4 cm apart from the lesion, in an area that did not have any visual signs of psoriasis (NL sample). Patients did not obtain any systemic or PUVA/UV treatment for 1 month before the biopsies. All biopsy samples were immediately transferred to the liquid nitrogen until RNA extraction.

RNA sequencing
--------------

A TissueLyser LT homogenizer (Qiagen, Valencia, CA, USA) was used to homogenize the biopsy specimens. Total RNA was extracted with the ExtractRNA reagent (Evrogen, Moscow, Russia) according to the manufacturer\'s protocol. Isolated RNA was dissolved in RNase-free water, rRNA was depleted using a RiboMinus Eukaryote Kit for RNA-seq (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA) and the samples were stored at −80 °C. The quality of total RNA was evaluated with an RNA 6000 Pico Chip Kit and an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA) and with a Quant-iT RNA Assay Kit and a Qubit fluorometer (Life Technologies). The average RNA integrity number of the samples was ⩾7. Library preparation and sequencing were performed using a SOLiD 4 System platform and sequencing chemistry according to the manufacturer\'s instructions (Life Technologies).

Processing and mapping of RNA-seq reads and differential expression analysis
----------------------------------------------------------------------------

Raw pair-end reads (50+25 bp) were obtained from the SOLID4 System (Applied Biosystems) in color space format (\*.csfasta) and were filtered for quality. The adaptor sequences were trimmed, and the reads were aligned to the UCSC human reference genome (hg19) using the Applied Biosystems Bioscope software (Applied Biosystems Bioscope, Thermo Fisher Scientific, Waltham, MA, USA) to obtain reads in the BAM format. Mapping to multiple locations was permitted. The aligned read BAM files were assembled into transcripts, their abundance was estimated and tests for differential expression were processed using the Bioconductor DESeq package (Simon Anders, EMBL, Heidelberg, Germany).^[@bib8]^ False discovery rate (FDR) correction for multiple testing was performed according to Benjamini *et al.*^[@bib9],\ [@bib10],\ [@bib11]^

Pathway analysis and identification of transcriptional regulators
-----------------------------------------------------------------

Using a fold change cutoff (FC)\>1.5 and a FDR\<0.05 and including only those genes that had reads at all samples, we identified 1564 DEGs: 938 of them were upregulated and 626 were downregulated. This subset of DEGs was used for gene ontology (GO) analysis using the DAVID tool (Database for Annotation, Visualization and Integrated Discovery ver. 6.7)^[@bib12]^ and pathway analysis as well as interactome analysis using the MetaCore database from Thomson Reuters (ver. 6.11, build 41105, GeneGo, Thomson Reuters, New York, NY, USA).^[@bib2]^ The MetaCore Pathway analysis tool was used to perform gene network enrichment analysis; the MetaCore Interactome tool was used for the identification of transcriptional regulators of DEG-enriched pathways.^[@bib2]^ The transcriptional regulators of DEGs were ranked by *Z*-score (representing the level of connectivity) and calculated as follows:

*N* is the total number of nodes (genes) after filtration; *R* is equal to either the number of nodes in the input list or the nodes associated with the experimental data; *n* is the number of the nodes in the network; *r* is the number of the network\'s nodes associated with the experimental data or included in the input list; *μ* and *σ* are the mean and dispersion of the corresponding hypergeometric distribution, respectively.

The cisExpress algorithm^[@bib3],\ [@bib4]^ was used for the identification of promoter motifs and the discovery of cis-elements in promoter sequences that are statistically associated with the expression patterns of DEG. Promoter sequences were obtained from the EPDnew database,^[@bib13]^ which is a collection of experimentally validated promoters in the human, mouse, fruit fly and zebrafish genomes. Evidence comes from transcription start site mapping from high-throughput experimental techniques, such as CAGE^[@bib14]^ and Oligocapping.^[@bib15]^ The positions of the promoters were validated using the NPEST algorithm.^[@bib16]^ We identified 16 542 *Homo sapiens* promoters with corresponding RNA-seq gene expression measurements in lesional and non-lesional skin.

The relative expression (R.E.) values for every gene were calculated from average gene expression data for lesional (*n*=14) and non-lesional (*n*=14) skin according to the formula:

The *Z*-score for cisExpress data were calculated as follows:

*e*~with~(*w*,*k*) and *e*~without~(*w*,*k*) are average gene expression values; *Stdev*~with~(*w*,*k*) and *Stdev*~without~(*w*,*k*) are s.d. of gene expression values; and *n*~with~(*w*,*k*) and *n*~without~(*w*,*k*) are the number of sequences of genes containing and not containing the motif *w* in the *k*th window.

*FOXA1* target gene identification in the DEG list
--------------------------------------------------

The *FOXA1* target list was obtained by merging ChIP-seq data from GSE39241^[@bib17]^ and GSM1099031^[@bib18]^ using the edgeR^[@bib19]^ and DESeq^[@bib8]^ packages with default parameters and then cross-referencing the results with the DEG list.

Results
=======

Analysis of psoriasis-associated DEGs
-------------------------------------

In this study, we identified 1564 genes that were differentially expressed in psoriatic lesions (psoriatic DEGs): 938 of them were upregulated and 626 were downregulated. Analysis of the top 20 upregulated DEGs ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}) highlighted the importance of immune defense mechanisms, inflammatory response, taxis and chemotaxis of immune cells and alterations of epidermal differentiation in the pathogenesis of psoriasis. Our analysis suggests that the genes with the largest magnitude of expression changes are the 'response\' genes that contribute to the pathophysiological manifestations of psoriasis rather than the initiation of the disease. A majority of the top 20 downregulated genes ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}) were linked to lipid biosynthesis and lipid metabolism. Interestingly, among the top 20 downregulated genes, we detected a number of poorly characterized expression units, including possible pseudogenes, and non-coding RNAs. It remains an open question whether non-coding RNA enrichment is of any functional significance or just an indication of technology bias.

To identify the molecular basis of psoriatic pathology, GO analysis and MetaCore-guided pathway analysis were performed.^[@bib2]^ The results of the GO analysis ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}) generally supported the findings obtained with MetaCore pathway enrichment ([Figure 1](#fig1){ref-type="fig"}) and the analysis of top DEGs described above. A detailed discussion of a number of psoriasis-associated pathways is presented in the 'Discussion\' and '[Supplementary Materials](#sup1){ref-type="supplementary-material"}\' sections.

Transcriptional regulation
--------------------------

The skin serves as a first line of defense against pathogen invasion. The stimulation of different pathogen-sensing receptors (such as pathogen-recognition receptors) leads to the activation of antimicrobial defense (i.e. defensins and other gene clusters, [Supplementary Figures S1 and S2](#sup1){ref-type="supplementary-material"},[Supplementary Table S5](#sup1){ref-type="supplementary-material"}) that is orchestrated by a number of key transcription factors (TFs), including nuclear factor kappa B (NFκB), activator protein 1, cAMP response element-binding protein, interferon-regulatory factors (IRF) and others. Although the putative antigen leading to the activation of pro-inflammatory signaling in psoriasis has not yet been identified, it is widely accepted that the signaling cascades activated in the course of psoriatic inflammation are mainly the same as those stimulated during pathogen invasion. The activation of inflammatory and antiapoptotic proteins ultimately alerts the immune system of the invasion and induces the recruitment of leukocytes to the site of infection.^[@bib20]^

To ascertain the key regulatory 'hub points\' of the psoriatic networks, two independent approaches were used. The first of them utilizes the MetaCore Interactome enrichment tool^[@bib2]^ that evaluates the levels of connectivity between the nodes (that can be either proteins or genes), identifies overconnected nodes and, according to the node function, suggests possible transcriptional regulators that drive the observed pattern of gene expression in the entire data set. The second approach relies on the cisExpress algorithm,^[@bib3],\ [@bib4]^ which allows one to perform *de novo* discovery of the motif within the putative promoter regions of DEGs by means of comparison of these regions with the content of the HOCOMOCO^[@bib21]^ v9, JASPAR,^[@bib22]^ HumanTF 1.0^[@bib23]^ and footprintDB^[@bib24]^ databases of known TF-binding sites (TFBSs). Next the identified lists of transcriptional regulators were compared with the data compiled by Swindell *et al.*^[@bib25]^ using meta-analysis of transcriptomes of 237 psoriatic patients, a dictionary of 2935 putative TFBSs and the sites for unconventional DNA-binding proteins. Swindell *et al.*^[@bib25]^ identified psoriasis-response elements that were overrepresented upstream of psoriasis DEGs in putative promoters that were defined as sequences starting at 5 kb upstream and ending at 500 bp downstream from the major transcription start site.

### MetaCore-guided identification of transcriptional regulators

The MetaCore Interactome tool determines the density of interactions between each protein from a data set of interest and all other proteins, evaluates statistically significant interactions within the set and analyzes the functions of the selected interacting proteins.^[@bib2]^ Because proteins usually work in groups (such as protein complexes and pathways) that are defined by protein interactions, it is assumed that the relative connectivity of each hub reflects its relevance, or importance, and it may be used for the identification of transcriptional regulators of DEG-enriched signaling cascades. Even if the expression levels of the mRNA encoding the TF itself are not altered, for example, when the TF in question is predominantly regulated posttranscriptionally, the number of targets it interacts with depends on the state of its activation or suppression. Hence, the enrichment or the depletion of an interacting protein network indicates the activation or suppression of the TF that orchestrates the network.

We identified possible transcriptional regulators of DEGs (the TFs significantly associated with DEG list; [Supplementary Table S6](#sup1){ref-type="supplementary-material"}) and computed their *Z*-score---the degree of connectivity of the TF to the list of DEGs. The *Z*-score signifies a number of connections obtained between a TF and a list of DEGs in excess of the number of connections expected with a random set of genes of the same size. The identified 'Top\' transcriptional regulators of the DEGs ([Figure 2](#fig2){ref-type="fig"}) are ranked according to their *Z*-scores corresponding to the influence of the TFs on the pathological processes associated with the disease. Their regulation leads to the development of the main distinctive features of psoriasis. In the 'Top\' TF list, there are both cell type-specific TFs (for example, PU.1, which is a master regulator of myeloid cells^[@bib26]^) and ubiquitously expressed TFs associated with inflammatory pathways (for example, NFκB and IRF^[@bib27]^), which reflects alterations in cell populations in a plaque compared with the unaffected skin. In addition to the TFs commonly associated with psoriasis, we identified TFs that have not been previously associated with the disease ([Supplementary Table S7](#sup1){ref-type="supplementary-material"}).

Further analysis is needed to determine the roles of the identified DEGs in disease progression. To illustrate our hypothesis of their involvement in psoriasis, we analyzed one of the TFs, FOXA1, and its target genes, looking for possible associations with pathogenesis. Using the CHIP-seq data available from experiments GSE39241^[@bib17]^ and GSM1099031,^[@bib18]^ we have compiled a list of gene targets for this TF and compared it with the list of DEGs identified by RNA-seq ([Supplementary Table S12](#sup1){ref-type="supplementary-material"}). The intersection between the two lists was used in the GO enrichment analysis to reveal processes in psoriatic lesions regulated by this TF ([Supplementary Table S13](#sup1){ref-type="supplementary-material"}). FOXA1 was found to be associated with the immune alterations indicative for the disease as well as with the abnormalities of lipid metabolism.

### De novo analysis of transcriptional regulation of DEGs using the cisExpress algorithm

Another approach that we utilized for the identification of the transcriptional regulators of DEGs was based on the cisExpress algorithm.^[@bib3],\ [@bib4]^ cisExpress finds putative regulatory elements using a combination of sequence and expression information. We used 16 542 validated *H. sapiens* promoters that have corresponding RNA-seq gene expression measurements in lesional and non-lesional skin.

The length of a promoter region varies from gene to gene, and the identification of a 'promoter window\' containing the most important regulatory sequences for each gene is a separate challenge. Hence, for our analysis, we used the 'core promoter-5′ untranslated region\' of (+500, −500) base pairs around the transcription start site of each gene. The analyzed set of the promoters was examined for the presence of motifs (putative TFBSs), and the corresponding gene expression values were compared for genes whose promoters did and did not contain the motifs using a *t*-test. We compiled a ranked list of \>100 position-specific motifs in the promoter regions of DEGs ([Supplementary Table S8](#sup1){ref-type="supplementary-material"}).

The top 10 motifs in the ranked list have the highest influence on gene expression ([Table 1](#tbl1){ref-type="table"}). For every motif, a *Z*-score was calculated. Positive *Z*-score values suggest that the presence of the motif is associated with elevated levels of gene expression in non-lesional skin, while negative values show that the presence of the motif is associated with elevated levels of gene expression in lesional skin. The absolute value of the *Z*-score is used to calculate the confidence level of the influence of the motif on gene expression. The complete list of motifs is given in [Supplementary Table S9](#sup1){ref-type="supplementary-material"}.

The motifs were examined for similarity with known TFBSs. HOMOCO v9,^[@bib21]^ JASPAR 2014,^[@bib22]^ HumanTF 1.0^[@bib23]^ and footprintDB^[@bib24]^ databases were used for this analysis (see [Supplementary Table S9](#sup1){ref-type="supplementary-material"}). For example, one of the identified motifs (AAGATG) is related to the ETS1 TF, a negative regulator of Th17 cells,^[@bib28]^ which are one of the most important T-cell populations in psoriasis, and to GATA-3, a transcriptional regulator leading to T helper type 2 (Th2) polarization in the Th1/Th2-cell-type switch,^[@bib29]^ which is downregulated in psoriatic skin. The CCGGAA motif is associated with the TF ELK4, which is highly expressed in lesional psoriatic skin.^[@bib30]^

### Identification of the key transcriptional regulators of the psoriatic transcriptome

To find the key transcriptional regulators of the DEGs, we compared lists identified by the two computational approaches (MetaCore and cisExpress) and the results of Swindell *et al.*^[@bib25]^ Comparison of the three groups of transcriptional regulators (327 cisExpress-identified, 200 MetaCore-identified and 439 identified by Swindell *et al.*) ([Figure 3](#fig3){ref-type="fig"}) identified 42 common TFs representing the 'core\' TF regulators of the psoriatic transcriptome ([Table 2](#tbl2){ref-type="table"}).

The majority of elements of the 'core TF\' list are TFs associated with inflammation (NFκB, IRF9, JUN, FOS, SRF), the activity of T-cells in the psoriatic lesions (STAT6, FOXP3, NFATC2, GATA3, TCF7, RUNX1 etc.), hyperproliferation and migration of keratinocytes (JUN, FOS, NFIB, TFAP2A, TFAP2C) and lipid metabolism (TFAP2, RARA, VDR). There were several FOX ('fork-head\' box) family proteins in the list containing the evolutionary conserved 'fork-head\' or 'winged-helix\' DNA-binding domain. These proteins could work as active regulators of cell proliferation and metabolism and also serve as pioneer factors that de-condense chromatin, therefore facilitating the binding of other sequence-specific TFs to target enhancers, repressors and promoters, wiring global gene networks essential for cell fate decisions.^[@bib31]^ We also found 294 DEG-associated TFs not identified by Swindell *et al.*^[@bib25]^ Sixty-six of them were identified by cisExpress as well as by MetaCore ([Figure 3](#fig3){ref-type="fig"} and [Supplementary Table S10](#sup1){ref-type="supplementary-material"}). Among the negative regulators, there is the CAGAC motif, frequently found in Smad-responsive promoter regions. Smad TFs have a key role in cytokine signaling pathways. The Smad complex includes DNA-binding cofactors influencing the recruitment of transcriptional coactivators or corepressors.^[@bib32]^ Another TFBS with a negative association with gene expression in psoriatic lesions is the CACCC-box, a biding site for the Krüppel-like factors that can act as a transcriptional repressor.^[@bib33],\ [@bib34],\ [@bib35],\ [@bib36],\ [@bib37]^ Recently, Krüppel-like factors were reported to regulate epidermal proliferation and differentiation in humans and control the physiological reaction to counteract the abnormal differentiation and proliferation of keratinocytes.^[@bib38]^

Pathway analysis
----------------

To investigate the relationships between the DEGs, we performed gene network enrichment analysis using the MetaCore software. The top 10 signaling networks enriched with DEGs were mainly associated with different alterations in immune signaling present in the psoriatic lesions ([Figure 1](#fig1){ref-type="fig"}), for example, the map 'Immune response_IL-17 signaling pathway\' ([Figure 4](#fig4){ref-type="fig"}). This agrees with the hypothesis that the main feature of psoriasis is the cytokine storm and altered balance of cytokines, chemokines and growth factors regulating various immune and inflammatory responses (see [Supplementary Materials](#sup1){ref-type="supplementary-material"} for a detailed discussion). The main psoriasis-associated transcriptional regulators of this map are NFκB and C/EBPb, as defined by the overexpression of their target genes shown on the map (for example, *CCL2*, *CCL7*, *CCL20*, *HBD2*, *IL8*, *iNOS2* and so on) and the consequent activation of downstream processes important for disease pathogenesis (chemotaxis of neutrophils, dendritic and T cells, alterations in cell adhesion and antibacterial activity). All of the TFs on the map were identified in the Top15 list in MetaCore analysis ([Figure 2](#fig2){ref-type="fig"}) as well as in the cisExpress analysis ([Supplementary Table S8](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In psoriasis, the observed changes in the gene expression levels and the DEG enrichment of certain GO processes may be explained by two different disease-associated phenomena: changes in the transcription and degradation rates of mRNA and alterations in the composition of cells within the lesion, which is usually characterized by epidermal thickening, the accumulation of immune cells and thinning of the subcutaneous fat layer. Therefore, whether the differential expression observed between lesional and non-lesional psoriatic samples truly reflects alterations in intracellular signaling remains unclear.^[@bib37]^ The top 10 signaling pathways ([Figure 1](#fig1){ref-type="fig"}) highlighted the importance of the activation and chemotaxis of immune cells mediated by the locally enhanced production of pro-inflammatory cytokines and chemokines and increasing inflammation. The importance of different populations of T cells in the pathogenesis of the disease is illustrated by the DEG-enriched map 'Immune response: T-cell subsets secreted signals\' ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). It shows the shift of T-cell populations toward interleukin-17-producing types, indicating the activation and enhanced migration of psoriasis-specific populations of T cells to the lesional skin.

One of the main regulators of T-cell polarization and population maintenance is the regulatory T-cell (Treg) population ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). Alterations in the presence and activity of Tregs in the skin of psoriasis patients may trigger development of the disease.^[@bib39]^ The canonical transcriptional regulator of this cell population is the TF FOXP3. A recent study described a new population of Treg cells that carry a non-canonical marker, FOXA1, instead of the canonical FOXP3.^[@bib40]^ This population also has a suppressive role in autoimmunity as adoptive transfer of such cells inhibited experimental autoimmune encephalomyelitis in a *FOXA1*-and PD-L1-dependent manner.^[@bib40]^ Our analysis identified the upregulation of *FOXP3* (FC=2.30, FDR=0.001) and downregulation of *FOXA1* (FC=0.49, FDR=0.01) in psoriatic lesional skin. We found that most of the markers of Treg cells were overexpressed in the analyzed transcriptomic data (*CD4*, *CD47*, *CD69*, *PD-L1*) except for *FOXA1* itself. We hypothesize that the observed reduced expression of *FOXA1* represents differences between Treg populations in non-lesional and lesional psoriatic skin. We suggest that the inhibition of maturation of naive T cells into a *FOXA1+* Treg subpopulation (*CD4+FOXA1+CD47+CD69+PD-L1(hi)FOXP3−*) contributes to the development of the disease.

The TF FOXA1 is not T-cell specific; it is involved in the regulation of cell differentiation under normal and pathological conditions (in epithelial, prostate and breast cancers; in epithelial cells of the intestines and lungs; and in pancreatic cells and other tissues^[@bib41],\ [@bib42],\ [@bib43],\ [@bib44],\ [@bib45],\ [@bib46],\ [@bib47]^). During embryonic stem cell development and hepatic differentiation, *FOXA1* functions as a 'pioneer TF\' owing to its ability to engage condensed chromatin, bind nucleosome-assembled *FOXA1* regulatory elements and displace repressive linker histones in response to retinoic acid treatment and transforming growth factor-β signaling.^[@bib48]^

In addition to its role in hepatic epithelial differentiation, *FOXA1* is also involved in uroepithelial differentiation. Differentiation of the urothelium is a process governed by peroxisome proliferator-activated receptor-γ (PPAR-γ) that involves intermediary TFs such as *IRF-1* and *FOXA1*. siRNA knockdown of either *FOXA1* or *IRF-1* abrogates the PPAR-γ-induced induction of late/terminal urothelial differentiation-associated genes.^[@bib49]^ PPAR-γ is also an important regulator of keratinocyte differentiation as well as the formation of the horny layer of the epidermis, which is rich in lipids and important for the barrier function. Treatment of cultured human keratinocytes with ciglitazone, a PPAR-γ activator, increases the mRNA levels of involucrin and transglutaminase-1. Moreover, topical treatment of hairless mice with ciglitazone or troglitazone increases loricrin, involucrin and filaggrin expression. As *PPARγ* itself is downregulated according to the RNA-seq data (FC=0.39, FDR=0.0039), and it is an upstream regulator of *FOXA1* signaling, it could be speculated that aberrant fatty acid metabolism as well as the general metabolic disturbances observed in psoriasis could lead to impaired cell differentiation via the inhibition of *PPARg* and the associated inhibition of *FOXA1* expression in the skin.

Another possible consequence of reduced *FOXA1* expression is disturbed keratinocyte differentiation (more discussion on this topic is in the [Supplementary Materials](#sup1){ref-type="supplementary-material"}). To evaluate the putative contribution of *FOXA1* regulation to the development of the psoriatic process, we have compared lists of *FOXA1* targets, identified in ChIP-seq experiments by Hurtado *et al.*,^[@bib50]^ with the DEGs identified by our RNA-seq analysis. We demonstrated that *FOXA1* is a transcriptional regulator of the top DEGs that serve as major histopathological contributors ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}), encoding S100 proteins, serpins and genes for chemoattractant CXCL proteins. Among other important upregulated targets contributing to the disease were *HLA-DPB1* (an HLA class II beta chain paralog expressed in antigen-presenting cells; a risk allele for the disease^[@bib51]^), keratins 6B and 6C (activation markers of keratinocytes essential for the formation of keratin intermediate filaments that also take part in wound healing) and *PPARδ* (a TF overexpressed in psoriasis that enhances the proliferation of keratinocytes and is induced by *JUNB* in keratinocytes).^[@bib52]^ Among the downregulated targets were genes associated with lipid disturbances observed in psoriatic lesions, including known components of fatty acid metabolism such as the acyl-CoA wax alcohol acyltransferase gene *AWAT2*, the fatty acid elongase gene *ELOVL3*, the fatty acid-binding protein FABP4 and many others. Ontology analysis of the *FOXA1* target DEGs yielded a list of ontologies similar to the whole DEG list discussed above ([Supplementary Tables S11 and S12](#sup1){ref-type="supplementary-material"}). Comparison of the lists of ontologies showed that *FOXA1* is a part of a regulatory complex accounting for the most important psoriatic alterations and signaling cascades important for pathology. Thus this TF is a promising candidate for future investigations of psoriasis.

There are two potential limitations of our study: relatively small samples size (14 pairs) and the ethnic homogeneity of samples (only Caucasians). Earlier studies demonstrated that a sample set of this size is sufficient to identify DEGs.^[@bib53],\ [@bib54]^ Because the RNA sequencing coverage depth corresponds to a log-normal distribution, a parametric test such as *t*-test could be utilized to identify DEGs.^[@bib55]^ To evaluate the reproducibility of the results, we compared our list of DEGs with a recent large-scale transcriptomic analysis of psoriatic samples (92 samples of lesional skin and 82 samples of non-lesional skin)^[@bib37]^ that identified a larger number of DEGs (6254 DEGS, 4581 upregulated and 1673 downregulated genes, FC\>1.5, FDR\<0.05). We demonstrated that \>60% of the DEGs identified in our study matched the DEGs found by Li *et al.*^[@bib37]^ ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). Given the differences between the sequencing platforms, sample sizes and studied populations, the concordance of \>60% is truly remarkable.

To avoid admixture, our samples were obtained from Caucasian patients in the regions where the Caucasian population is predominant. A recent large trans-ethnic genome-wide meta-analysis (15 369 psoriasis cases and 19 517 controls of Caucasian and Chinese ancestries) revealed population-specific effects or allelic heterogeneity for 11 susceptibility loci and noted that such population-specific effects contribute significantly to the ethnic diversity of psoriasis prevalence and may influence the course of disease.^[@bib56]^ Therefore, our data containing only Caucasian samples allows us to zoom in on immuno-pathogenesis and important psoriasis-associated pathways in Caucasian population. Additional studies should be conducted to evaluate the applicability of such data to the different ethnic groups.

In conclusion, our analysis highlighted the importance of immune system alterations in the development of psoriasis. We presented a list of identified core transcriptional regulators of the psoriatic transcriptome that can be validated to provide insight into the mechanisms of gene regulation in psoriasis. We also identified novel transcriptional regulators of psoriasis-associated pathways previously not implicated in the pathology. The comparison of our data with public ChIP-seq data allowed us to suggest a hypothesis explaining the role of the TF *FOXA1* in psoriasis.
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![Top 10 DEG-enriched signaling pathways. Sorted by statistical significance of the findings. The results were obtained using the MetaCore pathway analysis tool (GeneGO/Thomson Reuters).](emm201697f1){#fig1}

![Top 15 transcriptional regulators of DEG genes (identified with MetaCore Interactome). Transcription factors are ranked according to their *Z*-score (the level of connectivity of the TF to the DEG list). Larger *Z*-scores represent higher levels of connectivity between the transcription factor and the DEG list. The colors from red to violet indicate *Z*-score values from higher (16.14) to lower (10.48). The width of the ribbon for the transcription factor corresponds to the number of target genes for the transcription factor in the DEG list (for example, for the *STAT1* gene, the *Z*-score is 16.14, and the number of regulated DEGs is 76). The numerical data for this figure are in [Supplementary Table S6](#sup1){ref-type="supplementary-material"}.](emm201697f2){#fig2}

![Venn diagram showing overlap between lists of transcriptional regulators of DEG. green, identified by the MetaCore Interactome software; Violet, TFs identified by the cisExpress tool; yellow, identified in Swindell *et al.*^[@bib25]^](emm201697f3){#fig3}

![Immune response_IL-17 signaling pathway. Illustration generated with the MetaCore pathway analysis tool (GeneGO/Thomson Reuters) and enriched with DEGs. A description of the map symbols is in [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}. The red bars near the gene name illustrate the level of gene overexpression. Green arrows indicate signaling cascades enriched with DEGs. Orange circles indicate important transcription regulators of DEGs present in the map. Red circles indicate downstream signaling cascades activated by the pathway in lesional psoriatic skin.](emm201697f4){#fig4}

###### Top 10 motifs with the highest confidence of influence on gene expression identified with cisExpress
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###### Core TF regulators of the psoriatic transcriptome

  *Ensembl Gene ID*   *Gene symbol*   *Transcription factor name*
  ------------------- --------------- -----------------------------------------------------------------------------------
  ENSG00000067955     CBFB            Core-binding factor, beta subunit
  ENSG00000105516     DBP             D site of albumin promoter (albumin D-box)-binding protein
  ENSG00000101412     E2F1            E2F transcription factor 1
  ENSG00000164330     EBF1            Early B-cell factor 1
  ENSG00000120738     EGR1            Early growth response 1
  ENSG00000134954     ETS1            v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)
  ENSG00000170345     FOS             v-fos FBJ murine osteosarcoma viral oncogene homolog
  ENSG00000125798     FOXA2           Forkhead box A2
  ENSG00000111206     FOXM1           Forkhead box M1
  ENSG00000150907     FOXO1           Forkhead box O1
  ENSG00000118689     FOXO3           Forkhead box O3
  ENSG00000128573     FOXP2           Forkhead box P2
  ENSG00000049768     FOXP3           Forkhead box P3
  ENSG00000107485     GATA3           GATA-binding protein 3
  ENSG00000162676     GFI1            Growth factor independent 1 transcription repressor
  ENSG00000135100     HNF1A           HNF1 homeobox A
  ENSG00000101076     HNF4A           Hepatocyte nuclear factor 4, alpha
  ENSG00000213928     IRF9            Interferon regulatory factor 9
  ENSG00000177606     JUN             Jun oncogene
  ENSG00000169926     KLF13           Kruppel-like factor 13
  ENSG00000106689     LHX2            LIM homeobox 2
  ENSG00000099326     MZF1            Myeloid zinc finger 1
  ENSG00000101096     NFATC2          Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2
  ENSG00000147862     NFIB            Nuclear factor I/B
  ENSG00000165030     NFIL3           Nuclear factor, interleukin 3 regulated
  ENSG00000109320     NFKB1           Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  ENSG00000143190     POU2F1          POU class 2 homeobox 1
  ENSG00000131759     RARA            Retinoic acid receptor, alpha
  ENSG00000159216     RUNX1           Runt-related transcription factor 1
  ENSG00000186350     RXRA            Retinoid X receptor, alpha
  ENSG00000175387     SMAD2           SMAD family member 2
  ENSG00000143842     SOX13           SRY (sex determining region Y)-box 13
  ENSG00000125398     SOX9            SRY (sex determining region Y)-box 9
  ENSG00000112658     SRF             Serum response factor (c-fos serum response element-binding transcription factor)
  ENSG00000166888     STAT6           Signal transducer and activator of transcription 6, interleukin-4 induced
  ENSG00000162367     TAL1            T-cell acute lymphocytic leukemia 1
  ENSG00000071564     TCF3            Transcription factor 3 (E2A immunoglobulin enhancer-binding factors E12/E47)
  ENSG00000081059     TCF7            Transcription factor 7 (T-cell specific, HMG-box)
  ENSG00000148737     TCF7L2          Transcription factor 7-like 2 (T-cell specific, HMG-box)
  ENSG00000137203     TFAP2A          Transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha)
  ENSG00000087510     TFAP2C          Transcription factor AP-2gamma (activating enhancer-binding protein 2gamma)
  ENSG00000111424     VDR             Vitamin D (1,25-dihydroxyvitamin D3) receptor

Abbreviation: TF, transcription factor.
